Elvina Almuradova: Effect of KRAS mutations on survival outcomes in metastatic pancreatic cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, posted on LinkedIn about recent paper by Carter Norton et al., titled “KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma” published on JAMA Network.
Authors: Carter Norton, Matthew Steven Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P. Soares, Christopher D. Nevala-Plagemann, Ignacio Garrido-Laguna, Vaia Florou
“A recent study in JAMA Network analyzed the effect of KRAS mutations on survival outcomes for 2433 patients with metastatic pancreatic cancer.
Key findings:
- KRAS Mutations Matter:
G12D and G12V mutations linked to worse progression and survival outcomes.
G12R mutation showed better survival rates. - Treatment Matters Too:
The FOLFIRINOX regimen outperformed gemcitabine-based therapies in improving outcomes. - Takeaway: The type of KRAS mutation impacts treatment response, emphasizing the need for targeted and effective therapies for pancreatic cancer patients.”
Dr. Elvina Almuradova is an Associate Professor of Oncology at the European Institute of Oncology (IEO) and an Ambassador for the European School of Oncology. Her expertise encompasses basic oncology, chemotherapy, cancer biomarkers, diagnostics, and cancer cell biology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023